Pancreatic alpha and beta cell fate choice is directed by apical-basal polarity dynamics
A central question in cell and developmental biology is how extracellular cues control the differentiation of multipotent progenitors in a dynamically changing niche. Here, we identify apical-basal polarity as the main regulator of the differentiation of multipotent pancreatic Neurogenin3<sup>+</sup> endocrine progenitors (EPs) into the beta or alpha cell fates. We show that human EPs dynamically change their apical-basal polarity status. Whereas polarized EPs are predisposed to differentiate into beta cells rather than alpha cells, inhibiting apical-basal polarity selectively suppresses beta cell differentiation. Single-cell RNA sequencing and complementary mechanistic data demonstrate that apical-basal polarity in human EPs promotes beta cell specification via cyclic AMP (cAMP)/PKA-cAMP response element binding protein (CREB)-EGR1-mediated inhibition of ARX expression, while reduced cAMP levels in non-polarized human EPs maintain expression of ARX, leading to alpha cell differentiation. These findings identify the apical-basal polarity status of multipotent EPs as a critical epithelial feature that determines their fate into the alpha or beta cell lineages.
Authors
- Henrik Semb (ORCID: https://orcid.org/0000-0002-6747-787X)
- Y. Peter Di (ORCID: https://orcid.org/0000-0003-2028-2087)
- Martin Proks (ORCID: https://orcid.org/0000-0002-8178-3128)
- Jakub Sedzinski (ORCID: https://orcid.org/0000-0002-1788-0329)
- Ivan Kulik (ORCID: https://orcid.org/0000-0001-9033-1839)
- Ulf Tiemann
- Chenglei Tian (ORCID: https://orcid.org/0000-0002-5705-2851)
- Florian Hermann (ORCID: https://orcid.org/0000-0001-9499-7419)
- Emilie Skovgaard
Institutions
- University of Copenhagen (DK)
- Novo Nordisk Foundation (DK)
- Helmholtz Zentrum München (DE)
Publication Details
- Journal
- Developmental Cell
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1016/j.devcel.2025.02.008
- Citations
- 5
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 10.03
Funders
- European Commission
- Deutsche Forschungsgemeinschaft
- Novo Nordisk
- Novo Nordisk Fonden